Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy by Kim, H K et al.
ORIGINAL ARTICLE
Three-gene predictor of clinical outcome
for gastric cancer patients treated with
chemotherapy
HK Kim
1,2,I JC h o i
2,C GK i m
2,
HS Kim
2, A Oshima
1,YY a m a d a
3,
TA r a o
4, K Nishio
4,
A Michalowski
1 and JE Green
1
1Laboratory of Cancer Biology and Genetics,
National Cancer Institute, Bethesda, MD, USA;
2National Cancer Center, Goyang, Gyeonggi,
Republic of Korea,
3National Cancer Center,
Tokyo, Japan and
4Kinki University School of
Medicine, Osaka-Sayama, Japan
Correspondence:
Dr JE Green, Laboratory of Cancer Biology and
Genetics, National Cancer Institute, 37
Convent Drive, Bethesda, MD 20892, USA.
E-mail: JEGreen@mail.nih.gov
Received 23 March 2010; revised 10 October
2010; accepted 17 October 2010;
published online 21 December 2010
To identify transcriptional profiles predictive of the clinical benefit of cisplatin
and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic
biopsy samples from 96 CF-treated metastatic gastric cancer patients were
prospectively collected before therapy and analyzed using high-throughput
transcriptional profiling and array comparative genomic hybridization.
Transcriptional profiling identified 917 genes that are correlated with poor
patient survival after CF at Po0.05 (poor prognosis signature), in which
protein synthesis and DNA replication/recombination/repair functional
categories are enriched. A survival risk predictor was then constructed using
genes, which are included in the poor prognosis signature and are contained
within identified genomic amplicons. The combined expression of three
genes—MYC, EGFR and FGFR2—was an independent predictor for overall
survival of 27 CF-treated patients in the validation set (adjusted P¼0.017),
and also for survival of 40 chemotherapy-treated gastric cancer patients in a
published data set (adjusted P¼0.026). Thus, combined expression of MYC,
EGFR and FGFR2 is predictive of poor survival in CF-treated metastatic gastric
cancer patients.
The Pharmacogenomics Journal (2012) 12, 119–127; doi:10.1038/tpj.2010.87;
published online 21 December 2010
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Introduction
Although the emerging area of targeted anticancer agents holds great promise,
cytotoxic chemotherapy remains the primary treatment option for many cancer
patients. Identifying patients who likely will or will not benefit from cytotoxic
chemotherapy through the use of biomarkers could greatly improve clinical
management by better defining appropriate treatment options for patients. None
of the molecules experimentally identified to cause chemotherapy resistance
in vitro was sufficiently validated in primary tumors and thus clinically
applicable,
1 underscoring the importance of well-designed, clinical study to
identify clinically relevant mechanisms for chemotherapy resistance. In fact,
however, such predictors derived to date from high-throughput transcriptional
profiling of primary tumors, especially gastrointestinal tract cancers, have not
shown satisfactory performance.
2–5 It may be primarily owing to the high rate of
false-positive discovery in high-throughput data, in addition to the high degree
of genetic variation of individual tumor compared with limited number of
samples available for the study.
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www.nature.com/tpjTo provide insight into clinically relevant mechanisms for
chemotherapy resistance in gastric cancer, we prospectively
collected and analyzed 123 endoscopic biopsy samples
before cisplatin and fluorouracil (CF) chemotherapy from
patients with extended follow-up, using high-throughput
transcriptional profiling and comparative genomic hybridi-
zation (CGH) analyses. We could identify functional
categories enriched in genes correlated with patient out-
come, and develop a genomic predictor that was validated
in two independent data sets.
Materials and methods
Patients
Sample collection, treatment and follow-up were performed
according a protocol approved by the Institutional Review
Board of the National Cancer Center Hospital in Goyang,
Korea (NCCNHS01-003). All patients signed an Institutional
Review Board-approved informed consent form. Eligibility
for enrollment into the study included the following
parameters: (1) ageX18 years; (2) histologically confirmed
gastric adenocarcinoma; (3) clinically documented distant
metastasis; (4) no previous or concomitant malignancies
other than the gastric cancer; (5) no previous history
of chemotherapy, either adjuvant or palliative; and (6)
adequate function of all major organs. Patients who were
lost to follow-up before completing six cycles of chemother-
apy, except for documented progressive disease, were
excluded from this study.
Sample size calculation
Overall survival was the primary clinical end point of this
study. As a minimum of 91 events were estimated to be
required for the number of training set samples
6 at a¼0.001,
b¼0.05, t (standard deviation of log intensity)¼0.75 and d
(hazard ratio (HR) associated with one-unit change of
log intensity)¼2, we used the 96 samples collected until
January 2005 as the training set for development of the
predictor.
Ninety-six eligible patients who were treated with CF by
one medical oncologist (HK) from August 2001 to January
2005 were used for the expression profiling training set.
A second group of 27 eligible patients was used as the array
validation cohort. Twenty-two patients in the validation
cohort were treated with CF, and five patients were treated
with cisplatin plus oral capecitabine (a fluorouracil pro-drug
considered equivalent to fluorouracil; CX),
7 by another
group of medical oncologists in the same institution
between February 2005 and April 2006. Tissue procurement
and processing were the same for the training and validation
samples.
Treatment
Patients continued therapy indefinitely until they experi-
enced unacceptable toxicities or progressive disease
was documented. CF-treated patients received cisplatin
60mgm
 2 intravenously on day 1 and fluorouracil
1000mgm
 2 intravenously on days 1–5 of a 3-week
schedule. The treatment schedule for fluorouracil could be
shortened at the discretion of the oncologist to 3 instead of
5 days for elderly patients (X70 years) or patients with
poor performance status (Eastern Cooperative Oncology
Group performance status X2). Chemotherapy doses were
reduced according to toxicities and the patient’s perfor-
mance status. Specific dose modification schemes for
the subsequent cycle were left to the discretion of
treating oncologist. Five patients (18.5%) in the validation
group received oral capecitabine (Xeloda; Roche, Basel,
Switzerland; 1250mgm
 2 twice a day for 2 weeks) instead
of intravenous infusion of fluorouracil. Time to progression
was measured from the initiation of chemotherapy to the
progressive disease. In patients without any measurable
lesions, time to progression was measured to the time when
a change in therapy was required because unmeasurable
lesions (such as ascites) unequivocally progressed.
Gene expression and CGH microarray analyses
Tissue samples were collected and processed for RNA and
DNA extraction as described previously,
8 only if samples
contained at least 50% tumor cells. Affymetrix (Santa Clara,
CA, USA) HG-U133A gene expression microarray data were
analyzed with survival analysis algorithms of BRB-Array-
Tools (version 3.6, National Cancer Institute, http://linus.
nci.nih.gov/BRB-ArrayTools.html).
9 The survival risk groups
were constructed using a predictive index based on the
supervised principal component method of Bair and
Tibshirani.
10 A three-gene predictive index percentile was
generated based on the weighted average of the log
intensities of the three genes (FGFR2 (211401_s_at), EGFR
(210984_x_at) and c-MYC (202431_s_at)), using a propor-
tional hazards regression on the first two principal compo-
nents of the log intensities of those three genes, in which a
high value of the predictive index corresponds to a high risk
of death. If the predictive index of a sample in the validation
set corresponded to the median predictive index of the
training set, the sample was assigned a 50% predictive
index. We specified the number of risk groups as 2 (high and
low) and the predictive index percentile for defining the two
risk groups as 67%, using a 67.1% rate of clinical benefit
(partial response and stable disease) and 32.9% rate of
progressive disease in the training set. We also performed
Cox regression analyses using this three-gene predictive
index percentile as a continuous variable, in which HRs for
survival were calculated according to each percentile
increase in three-gene predictive index percentile (from 0
to 100%). Array CGH data were generated using Agilent
(Santa Clara, CA, USA) 4 44k HD-CGH Microarrays and
analyzed using CGH Analytics software (version 3.5.14).
Aberrations with average tumor/normal log2 ratio 42.0
were defined as amplifications. Experimental details are
provided in Supplementary Materials and Methods.
Analyses of published DNA microarray data
The entire set of published Affymetrix U133 Plus 2.0 DNA
microarray data
4 (n¼40) was combined with our training
set data (n¼96), using common probe set IDs. MAS5 data of
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using the median over the entire arrays and analyzed
for survival risk prediction using BRB-ArrayTools 3.6, as
described above.
Publicly accessible microarray data for surgically treated
gastric cancer patients generated by the Stanford Functional
Genomics Facility were obtained from the NCBI GEO
database (GSE4007) and included about 30300 genes
common to these data sets. The microarray data were
generated and normalized as described in Leung et al.
11
Batch effects in gene expression were removed with probe-
wise mean centering and missing data were imputed with
the nearest-neighbor averaging method.
12 The array cDNA
clones were annotated using SOURCE (Stanford Microarray
Database) and the Entrez GeneID was used as the mapping
identifier for the Affymetrix HG-U133A array. A combined
data set of our training set data (n¼96) and GSE4007
data (n¼88) was analyzed for survival risk prediction using
BRB-ArrayTools 3.6 as described above.
Results
Genes correlated with poor survival after CF therapy
As primary gastric cancer lesions cannot be reliably mea-
sured by diagnostic imaging, patient survival, not radio-
graphic response, was used as the primary clinical covariate
to which gene expression was correlated to identify a
predictor of response to CF therapy. To define a gene
expression signature that correlates with overall survival,
we used expression array data of 96 pretreatment biopsy
samples as the training set to develop a predictor (Supple-
mentary Table 1). Ninety-five out of 96 patients (99%) in the
training set cohort died with follow-up for one survivor at
39.4 months. None of the clinicopathological or treatment
factors listed in Table 1, including second-line chemother-
apy, were significantly correlated with survival time of the
patients in the training set.
To identify a transcriptional profile related to clinical
benefit from CF therapy, the survival times of patients in the
array training set were correlated with the mRNA expression
levels measured by microarray. One thousand five hundred
and sixty-five genes were significantly correlated with the
overall survival of the 96 patients (P-value o0.05). Among
them, 917 genes had an HR higher than 1 (poor prognosis
signature) and 648 genes had an HR lower than 1 (good
prognosis signature). We performed gene ontology analyses
on this ‘poor prognosis signature’ using Ingenuity Pathway
Analysis (www.ingenuity.com). The role of BRCA1 in DNA
damage response (BRCA2, E2F5, FANCE, MSH2, NBN,
PLK1, RFC, SMARCA4, SLC19A1), nucleotide excision repair
(ERCC2, POLR2C, POLOR2J, RAD23A, RAD23B) and estrogen
receptor signaling were highly represented canonical path-
ways. Many of these poor prognosis signature genes belonging
to these three pathways are previously linked to in vitro
cisplatin resistance.
13–15 Overexpression of ERCC2 (P¼0.007
in our data) is associated with cisplatin resistance in lung
cancer cell lines.
13 Silencing of hHR23A (P¼0.022 in our
data) decreases the nuclear DRP1 level and cisplatin
resistance in lung adenocarcinoma cells.
14 Disruption of
the Fanconi anemia–BRCA pathway is reported in cisplatin-
sensitive ovarian tumors.
15 Thus, this gene ontology
analysis supports the clinical relevance of these DNA repair
Table 1 Clinicopathological characteristics of patients
Training
set
(n¼96)
Validation
set
(n¼27)
Baseline clinicopathological characteristic
Age, no. (%)
o70 years 90 (93.8%) 25 (92.6%)
X70 years 6 (6.2%) 2 (7.4%)
Sex, no. (%)
Male 73 (76.0%) 23 (85.2%)
Female 23 (24.0%) 4 (14.8%)
PS, no. (%)
ECOG PS 0 or 1 91 (94.8%) 25 (92.6%)
ECOG PS 2 or 3 5 (5.2%) 2 (7.4%)
Histological type, no. (%)
Lauren’s intestinal 40 (41.7%) 9 (33.3%)
Lauren’s diffuse 56 (58.3%) 18 (66.6%)
Location of primary lesion, no. (%)
Upper 1/3 14 (14.6%) 2 (7.4%)
Middle 1/3 28 (29.2%) 10 (37.0%)
Lower 1/3 49 (51.0%) 15 (55.6%)
Entire stomach 5 (5.2%) 0
Distant metastasis, no. (%) 96 (100%) 27 (100%)
Tumor cell percentage in sample (%)
Median 60 70
Interquartile range 50–70 55–80
Treatment and outcome
Chemotherapy regimen, no. (%)
Cisplatin/fluorouracil 96 (100%) 22 (81.5%)
Cisplatin/capecitabine 0 (0%) 5 (18.5%)
Relative dose intensity (%)
Median 79 81
Interquartile range 73–88 72–87
Number of chemotherapy cycles
Median 4 7
Interquartile range 3–9 5–13
Response (WHO criteria), no. (%)
PR 38 (44.7%) 12 (48.0%)
SD 19 (22.4%) 9 (36.0%)
PD 28 (32.9%) 4 (16.0%)
Non-measurable disease 11 2
Second-line chemotherapy, no. (%) 69 (71.9%) 19 (70.4%)
Median follow-up for survivors
(months)
39.4 30.4
Overall survival (months)
Median 8.1 12.6
Interquartile range 5.6–15.9 7.4–30.4
Time to progression (months)
Median 3.9 6.3
Interquartile range 2.2–8.3 3.9–14.6
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD, progressive
disease; PR, partial response; PS, performance status; SD, stable disease; WHO,
World Health Organization.
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with in vitro cisplatin resistance.
Ingenuity Pathway Analysis functional categories en-
riched in poor prognosis signature were: protein synthesis,
DNA replication/recombination/repair and cancer (Supple-
mentary Table 2). The protein synthesis category includes
ribosomal subunit mRNAs (RPL13, RPL18, RPL24, RPL30,
RPL38, RPL5, RPL7, RPL7A, RPL8, RPS2, RPS5) and eukar-
yotic translation initiation factors (EIF1, EIF2B2, EIF2B4,
EIF2S1, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3H, EIF3I,
EIF4A1, EIF4A3, EIF4B, EIF4EBP1, EIF5, EIF5B). This result
suggests that the most prominent feature of poor prognosis
signature is increased protein synthesis, presumably result-
ing from activation of oncogenes, such as EGFR, FGFR2 and
MYC (Supplementary Table 2). MYC-induced transcriptional
activation of protein synthesis-related genes is previously
shown by a microarray report that the majority of genes
responsive to MYC overexpression are involved in macro-
molecular synthesis, protein turnover and metabolism,
including 30 ribosomal protein genes.
16
Infinitesimal perturbation analysis canonical pathways
enriched in 648 genes in good prognosis signature were
antigen presentation pathway, B-cell development and
interleukin-15 production. Enriched functional categories
were gastrointestinal disease, inflammatory disease and
genetic disorder.
Development of the three-gene predictor
Although such a gene ontology analysis of the whole
signature provides some insight into clinically relevant
mechanisms for chemotherapy resistance, this large number
of genes is not readily amenable to clinical application.
Therefore, we wished to narrow down 917 genes in the
whole poor prognosis signature to the smaller number of
genes, which may have driven the expression of majority of
genes in the signature. Focusing on such ‘driver gene’
candidates would also minimize the chance of including
false-positive discovery in a genomic predictor. For this
purpose, a second tier of genomic analysis was performed to
identify genes that could be functionally important in
gastric cancer cells.
Genomic DNA from samples available from the training
set patients was analyzed by array CGH to identify gene
amplifications. Age, sex and overall survival were similar
between the 30 patients (31.3%) whose samples were
analyzed by array CGH and the other patients in the
training set. Using very conservative criteria (average
tumor/normal log2 ratio 42.0 for X5 consecutive CGH
probes), nine amplicons were identified in 11 patients
(Table 2). We identified genes found in both the 1565 gene
expression signature whose transcriptional levels correlated
with poor survival of 96 training set patients (P-value
o0.05) and that are also located within the nine amplicons
identified by the array CGH. Three genes—MYC (8q24.13–
24.21), EGFR (7p11.2) and FGFR2 (10q26)—were identified
in the amplicons (Table 2) whose expression array signal
values significantly correlated with the survival time of the
96 patients in the training set (Figure 1). Patients with EGFR
and FGFR2 amplifications had higher expression levels of
each gene (8.4 and 10.2±0.8 (mean±s.d.), for EGFR and
FGFR2, respectively) than tested patients without the
amplification of these genes (5.9±1.0 and 5.2±1.1, for
EGFR and FGFR2, respectively). One of the two patients with
MYC amplification had higher expression than patients
without amplification (10.9 vs 9.5±0.9).
The mRNA expression array signal values of these three
genes were correlated with the short survival time with
P-values of 0.0154, 0.0096 and 0.0057, for MYC, EGFR and
FGFR2, respectively. The expression patterns of these three
Table 2 Amplicons identified using array CGH
a
Cytoband Start End Target gene No. of
patients
3q27.1 185763900 185763959 EPHB3 1
5q33.1 149481646 149514673 PDGFRB 1
7p11.2 54746103 55363004 EGFR 1
8q24.13–
24.21
126357675 128822455 MYC 2
9p13.3 33745689 33961753 PRSS3, UBE2R2,
UBAP2
1
10q26 123264724 13123458467 FGFR2 2
17q12 35046052 35282145 ERBB2 2
17q21.2 36110139 36230022 KRT24, KRT25A,
KRT25C,
KRT25D, KRT10
2
17q21.2 36569493 36888515 KRTAP4-4,
KRTAP4-10,
KRTAP9-9,
KRTAP9-4,
KRTAP17-1,
KRTHA3A,
KRTHA3B,
KRTHA4,
KRTHA1,
KRTHA7,
KRTHA8,
KRTHA2,
KRTHA5
1
Abbreviation: CGH, comparative genomic hybridization.
aDefined by aberrations with average tumor/normal log2 ratio 42.0 for X5
consecutive probes.
Figure 1 Three genes—EGFR, FGFR2 and MYC—overlap between
genes whose array expression levels correlated with survival times
(96 training set patients, Po0.05) and gene copy number changes
determined by array comparative genomic hybridization (CGH)
(tumor/normal log2 ratio 42 for X5 consecutive probes).
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patients are depicted in the heatmap in Figure 2. None of
the three genes had significantly different expression
levels between those patients who received second-line
chemotherapy and those who did not. Quantitative real-
time RT-PCR and immunohistochemical staining for the
three genes validated the array expression data (Supple-
mentary Figures 1 and 2).
A three-gene predictive index percentile was then calcu-
lated for each of the 27 patients in the validation cohort,
based on the weighted average of the log intensities of these
three genes for each sample (designated as the three-gene
predictor). Patterns of MYC, EGFR and FGFR2 expression in
these 27 patients, together with the predictive index, are
graphically displayed in Figure 2. As a continuous variable,
the three-gene predictive index percentile is an independent
predictor for poor survival in the validation set by Cox
regression analyses, after considering age, performance
status, histological type and second-line chemotherapy
(adjusted P¼0.017) (Table 3). Patients predicted to have
poor survival after CF using a predictive index percentile
X67% had a significantly shorter median survival
than patients with a predictive index percentile o67%
(7.4 months for the high-risk group vs 16.8 months for the
Table 3 Cox regression analyses of the three-gene predictive index percentile, as a continuous variable, for 27 patients in the
validation set
Overall survival Time to progression
P-value HR (95% CI) P-value HR (95% CI)
Univariate
Three-gene predictive index percentile
a 0.050 1.015
b (1.000–1.030) 0.026 1.017 (1.002–1.031)
Multivariate
Three-gene predictive index percentile 0.017 1.023 (1.004–1.042) 0.014 1.023 (1.005–1.043)
Age X70 years
c 0.027 7.614 (1.257–46.130) 0.144 3.605 (0.646–20.112)
Poor performance status (ECOG PS 2 or 3) 0.346 2.130 (0.442–10.258) 0.074 4.829 (0.861–27.086)
Second-line chemotherapy 0.041 4.231 (1.064–16.831) 0.011 5.992 (1.502–23.902)
Diffuse histological type 0.773 1.164 (0.415–3.263) 0.280 1.774 (0.626–5.025)
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.
aComputed based on weighted average of log intensities of the three genes (EGFR, FGFR2 and MYC) obtained using a proportional hazards regression on the first two
principal components of the log signal intensities of those three genes.
bHR for each percentile increase in three-gene predictive index percentile. For example, a predictive index percentile of 100 (the highest predictive index) is associated
with an HR of 4.4 (¼1.015
100), compared with a predictive index percentile of 0 (the lowest predictive index). The median predictive index (50%) is associated with
HRs of 2.1 (¼1.015
50), compared with the lowest predictive index.
cFor patients aged X70 years, the treatment schedule for fluorouracil could be shortened at the discretion of the oncologist to 3 instead of 5 days.
Figure 2 Affymetrix array expression levels of MYC, EGFR and FGFR2 in 96 training set samples (left) and 27 validation set samples (right), shown
with Kaplan–Meier plots for overall survival. Samples are ordered by the increasing survival period of patient from left to right, for the training and
validation sets, respectively. A three-gene predictive index for each patient based on the three-gene predictor is indicated below.
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risk group predicted by the three-gene predictor (patient
group with a predictive index percentile X67%) was
associated with an adjusted HR of 3.1 (95% CI, 1.2–8.4;
P¼0.022). In addition, the three-gene predictive index
percentile is also an independent predictor for the time to
progression, which is a more specific indicator of the clinical
responsiveness to systemic therapy than overall survival
17
(adjusted P¼0.014) (Table 3). We therefore show that,
independent of old age (X70 years), poor performance
status (Eastern Cooperative Oncology Group performance
status X2) and second-line chemotherapy, the three-gene
predictive index is predictive of the benefit from CF to
metastatic gastric cancer patients. An adjusted HR for
time to progression according to each percentile increase
in three-gene predictive index percentile was 1.023
(95% CI, 1.005–1.043) (that is, 100, 75 and 50% predictive
indices are associated with an HR of 9.7 (¼1.023
100), 5.5
(¼1.023
75) and 3.1 (¼1.023
50), respectively, compared with
a 0% predictive index).
Three-gene predictor predicts survival of patients in the
second validation set
To extend these results, we wished to test the predictive
power of the three-gene predictor in other independent
data sets. After the three-gene predictor was validated in
27 patient samples in our validation set, another microarray
study with a comparable study design to our study
was published in the literature.
4 These data were only one
published microarray data set that could be used to
determine whether the three-gene predictor could predict
the outcome of metastatic gastric cancer patients treated
with either cisplatin or fluorouracil. This data set contains
pretreatment expression array data for 40 patients who
subsequently received either fluorouracil-based chemother-
apy (n¼24) or cisplatin/irinotecan combination chemother-
apy (n¼16) and patient survival data. We applied the same
three-gene predictor to this published microarray data set,
just as we did to our 27 patient data in the first validation
set. The three-gene predictive index percentile, as a
continuous variable, was found to be significantly associated
with poor survival of these 40 patients (P¼0.047; HR
according to each percentile increase in three-gene
predictive index percentile¼1.014 (95% confidence inter-
val, 1.000–1.027)). Cox multivariate analysis showed that
the three-gene predictive index percentile is an independent
predictor for poor survival, after considering performance
status, age, sex and the chemotherapy regimen (adjusted
P¼0.026; adjusted HR¼1.017 (1.002–1.032)) (Table 4,
Figure 3b). Thus, the predictive power of the three-gene
predictor is consistent across two validation sets, that is, one
from our study patients and the other from published data.
Interestingly, the three-gene predictor was found to be an
independent predictor for poor survival, when the same Cox
regression analysis was performed only on a subset of these
patients (n¼16) treated with cisplatin in combination with
irinotecan, a topoisomerase I inhibitor (adjusted P¼0.011;
adjusted HR¼1.038 (1.008–1.068)). Patients treated with
irinotecan were not included in the original training
set patients. Hence, the predictive power of three-gene
predictor may not be specifically associated with only CF
therapy, although further large-scale studies need to be
Figure 3 (a) Kaplan–Meier survival curves for the two risk groups of the
validation cohort predicted by three-gene predictor. Patients at a high
risk (predictive index percentile X67%; n¼10) had significantly shorter
median survival than patients at a low risk (n¼17) (7.4 vs 16.8 months;
log rank P¼0.047). Green and blue lines represent overall survival
curves for the predicted high- and low-risk groups, respectively.
(b) Kaplan–Meier survival curves for the two risk groups of the published
microarray data set from 40 metastatic gastric cancer patients treated
with either fluorouracil-based regimens or cisplatin/irinotecan combina-
tion chemotherapy regimen. Patients at a high risk (predictive index
percentile X67%; n¼6) had shorter median survival than patients at a
low risk (n¼34), at a borderline significance (3.1 vs 10.8 months; log
rank P¼0.056). Green and blue lines represent overall survival curves
for the predicted high- and low-risk groups, respectively. The color
reproduction of the figure is available on the html full text version of the
manuscript.
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predictor for other therapeutic regimens.
Three-gene predictive index and radiographic response
Although the radiographic tumor response was not the main
end point of this study, we also evaluated the association
between the three-gene predictive index and radiographic
response of patients with measurable disease. When pub-
lished data
4 were also included, 104 patients had either
partial response or stable disease (clinical benefit) as the best
response, whereas 46 patients had progressive disease. The
three-gene predictive index was significantly associated with
radiographic response at a univariate P-value of 0.039,
which is higher than the Cox regression P-value for the
overall survival of all study patients (Table 5). This statistical
association was at borderline significance in a multivariate
regression analysis.
Three-gene predictor is not prognostic but predictive
Although we showed that the three-gene predictor predicted
time to progression and overall survival for CF-treated
patients, we wished to further address whether it represents
a prognostic signature, using the published data set from 88
gastric cancer patients who were treated by surgery alone
and not with chemotherapy.
11 The three-gene predictive
index percentile was not a prognostic factor in this data set
as a continuous variable (P¼0.506). There was no difference
in survival in the surgically treated patients between the
high- and low-risk groups predicted by the three-gene
predictor (P¼0.972). These results strongly suggest that
the three-gene predictor is not a predictor of prognosis for
gastric cancer patients, but is predictive of the patient
response to chemotherapy.
Discussion
Cytotoxic chemotherapy prolongs the median survival of
metastatic gastric cancer patients from 3–5 to 9–11 months
compared with best supportive care, with a response rate of
40–50%.
18–21 Combination CF constitutes the backbone
for chemotherapy regimens commonly used for gastric
cancers.
19,22 We also reported that CF in combination with
low-dose docetaxel is active for metastatic gastric cancer
with tolerable toxicity profile.
18 The ability to predict the
primary resistance of common solid tumors to cytotoxic
Table 5 Logistic regression analysis on the three-gene predictive index for radiographic response of 150 patients with
measurable disease, including patients represented by the published data set
Radiographic response
a Time to progression Overall survival
P-value OR (95% CI) P-value
b HR (95% CI) P-value
c HR (95% CI)
Univariate
Three-gene predictive index
d 0.039 2.001 (1.036–3.864) 0.020 1.304 (1.042–1.631) 0.030 1.288 (1.026–1.618)
Multivariate
Three-gene predictive index 0.059 1.902 (0.976–3.704) 0.019 1.309 (1.045–1.641) 0.018 1.316 (1.048–1.654)
Age X70 years 0.914 1.069 (0.318–3.598) 0.791 1.119 (0.486–2.577) 0.113 1.600 (0.895–2.862)
Poor performance status
(ECOG PS 2 or 3)
0.336 0.513 (0.132–1.999) 0.026 2.192 (1.097–4.381) 0.048 1.921 (1.004–3.677)
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OR, odds ratio; WHO, World Health
Organization
aNo clinical benefit (progressive disease according to the WHO criteria; n¼46) vs clinical benefit (partial response and stable disease; n¼104).
bResult of Cox regression analysis on the three-gene predictive index for the time to progression of 123 patients in the training and the first validation sets.
cResult of Cox regression analysis on the three-gene predictive index for the overall survival of all of 163 study patients including published data set.
dComputed based on weighted average of log intensities of the three genes (EGFR, FGFR2 and MYC) obtained using a proportional hazards survival regression on the
first two principal components of the log signal intensities of those three genes.
Table 4 Cox regression analyses of the three-gene predictive
index percentile, as a continuous variable, for published DNA
microarray data from 40 metastatic gastric cancer patients
treated with either FU-based chemotherapy or cisplatin/
irinotecan combination chemotherapy
Overall survival
P-value HR (95% CI)
Univariate
Three-gene predictive
index percentile
0.047 1.014 (1.000–1.027)
Multivariate
Three-gene predictive
index percentile
0.026 1.017
a (1.002–1.032)
Performance status X1 0.028 3.008 (1.129–8.016)
Age
b 0.766 0.995 (0.961–1.030)
Male 0.538 1.359 (0.512–3.605)
FU-based chemotherapy
regimen
c
0.744 0.854 (0.332–2.199)
Abbreviations: CI, confidence interval; FU, fluorouracil; HR, hazard ratio.
aAdjusted HR for each percentile increase in three-gene predictive index
percentile. For example, a predictive index percentile of 100 (the highest
predictive index) is associated with an HR of 5.4 (¼1.017
100), compared with a
predictive index percentile of 0 (the lowest predictive index).
bAs a continuous variable.
cAs compared with the irinotecan/cisplatin combination chemotherapy regimen.
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The Pharmacogenomics Journalchemotherapy is currently lacking, but would significantly
improve patient care by identifying those who would best be
treated by alternative strategies. This study has identified a
three-gene predictor that distinguishes gastric cancer
patients likely to receive a therapeutic benefit from CF from
those who will not.
Most previous studies attempting to identify predictors of
chemoresistance in gastric cancer have examined only
individual genes such as TS or ERCC1.
23,24 High-throughput
DNA microarray analyses to identify gene expression
signatures predictive of chemotherapy or chemoradiother-
apy resistance in gastrointestinal cancer patients have been
limited by the small number of samples,
2,3 heterogeneous
treatment
4 or were not prospectively designed.
5 In contrast
to these previous studies, our study uses high-throughput
genomic approaches, is prospective with a large, pre-defined
number of training set patients, separate validation cohorts
and survival data during an extended follow-up period.
Although previously reported TS and ERCC1 tend to be
associated with poor prognosis of our patients, the associa-
tion was not significant enough for them to be considered
for our predictive model (P¼0.073 and 0.076, for TS and
ERCC1, respectively). Notably, the outcome discrimination
predicted by the classifier was statistically significant on two
validation groups, including the only available published
microarray data set from chemotherapy-treated gastric
cancer patients.
4 Although the sample size of our validation
set is relatively small, it is nonetheless large enough to
show that our three-gene predictor provides a statistically
significant discrimination of patient outcome in multi-
variate survival analyses. The study design we employed
is consistent with an allocation of two-thirds to one-third
training-to-test set sample allocation as recommended
by statisticians.
25
We combined analyses of gene expression changes
identified by expression profiling with the identification of
DNA copy number changes using array CGH to develop a
predictor composed of a much smaller number of critical
genes that potentially could be of clinical utility. We
identified MYC, EGFR and FGFR2 in regions of amplifica-
tion, as well as in the gene expression signature related to
clinical outcome after CF therapy, suggesting that these
genes might be functionally involved in determining
resistance. Amplification of MYC, EGFR and FGFR2 have
previously been observed in gastric cancer at frequencies
4.8–15.5%,
26 2.3–13.3%
27 and 3–10%,
26,28 respectively,
suggesting that, in some cases, tumors amplify these regions
for selective advantage. Combined expression of these three
genes could predict overall survival and time to progression
of CF-treated gastric cancer patients. Thus, combining array
CGH analysis with relevant transcriptional changes is a
feasible approach for building a predictive model using
functionally important genes and reducing the likelihood
of false biomarker discovery. Transcriptional levels of
genes other than MYC, EGFR and FGFR2 identified in the
amplified genomic loci were not associated with the survival
of the 96 training set patients (for example, P¼0.313
for ERBB2).
Primary gastric tumors are not easily measurable by
current radiographic techniques, and often there are no
metastatic lesions that are readily quantifiable in metastatic
gastric cancer patients. To develop a predictor from the
general population of gastric cancer patients in an unbiased
way, this study was designed to correlate gene expression
profiling of the tumors with overall survival and time to
progression, not radiographic response. Overall survival is
the ultimate measure of the treatment benefit afforded to a
patient and is a particularly appropriate gauge for patients
with metastatic gastric cancer, as radiographic assessment is
problematic in such patients. The fact that both the time to
progression as well as overall survival are predicted by our
three-gene predictor in CF-treated patients, but not surgi-
cally treated patients, suggests that the three-gene predictor
is a predictive indicator for the clinical benefit from CF.
Although EGFR and FGFR2 expression have been reported
to have prognostic value for gastric cancer patients treated
surgically,
29,30 we did not find the three-gene predictive
index to be prognostic for surgically treated patients with
gastric cancer. Our findings are consistent with previously
reported experimental data on chemoresistance. Inhibitors
of EGFR act synergistically with cisplatin
31 and fluorour-
acil,
32 whereas an FGFR2 inhibitor is synergistic with
fluorouracil.
33 MYC has been linked to cisplatin resistance
in several in vitro models.
34–37
Taken together, combined expression of MYC, EGFR and
FGFR2 is predictive of poor survival in CF-treated metastatic
gastric cancer patients. More focused prospective trials that
are designed to test the clinical utility of this three-gene
predictor are warranted.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgments
The work was supported in part by National Institute of Health
Intramural Program, Center for Cancer Research, National Cancer
Institute, Korean National Cancer Center Grant 0910570 and
Converging Research Center Program through the Ministry
of Education, Science and Technology of Korea (2010K001121).
We thank Dr Richard Simon for valuable discussions and critical
reading of the manuscript, Dr Lyuba Varticovski for critical review
of the manuscript and Dr Chang-Hee Kim, Ms Susie Korolevich,
Ms Eunbyul Lee, Ms Eugene Kim and Ms Ilji Jeon for technical help.
Transcript Profiling
All expression microarray data is available at Gene Expression
Omnibus (accession number GSE14210; http://www.ncbi.nlm.
nih.gov/geo).
References
1 Uchida K, Danenberg PV, Danenberg KD, Grem JL. Thymidylate
synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine
phosphorylase gene expression in primary and metastatic gastro-
Three-gene predictive signature for gastric cancer chemotherapy
HK Kim et al
126
The Pharmacogenomics Journalintestinal adenocarcinoma tissue in patients treated on a phase I trial of
oxaliplatin and capecitabine. BMC Cancer 2008; 8: 386.
2 Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R,
Montagna C et al. Effectiveness of gene expression profiling for
response prediction of rectal adenocarcinomas to preoperative chemor-
adiotherapy. J Clin Oncol 2005; 23: 1826–1838.
3 Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K et al.
Microarray-based prediction of tumor response to neoadjuvant
radiochemotherapy of patients with locally advanced rectal cancer.
Clin Gastroenterol Hepatol 2008; 6: 53–61.
4 Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K et al.
Identification of prognostic biomarkers in gastric cancer using
endoscopic biopsy samples. Cancer Sci 2008; 99: 2193–2199.
5 Allen WL, Coyle VM, Jithesh PV, Proutski I, Stevenson L, Fenning C et al.
Clinical determinants of response to irinotecan-based therapy derived
from cell line models. Clin Cancer Res 2008; 14: 6647–6655.
6 Simon R, Radmacher MD, Dobbin K. Design of studies using DNA
microarrays. Genet Epidemiol 2002; 23: 21–36.
7 Kang Y, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al. Randomized
phase III trial of capecitabine/cisplatin vs continuous infusion of 5-FU/
cisplatin as first-line therapy in patients with advanced gastric cancer:
efficacy and safety results. J Clin Oncol 2006; 24 (Suppl): 18s (abstract
4018).
8 Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, Park IS et al. DNA microarray
analysis of the correlation between gene expression patterns and
acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys
Res Commun 2004; 316: 781–789.
9 Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of
gene expression data using BRB-Array Tools. Cancer Informatics 2007; 2:
11–17.
10 Bair E, Tibshirani R. Semi-supervised methods to predict patient survival
from gene expression data. PLoS Biol 2004; 2: E108.
11 Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J et al. Phospholipase
A2 group IIA expression in gastric adenocarcinoma is associated with
prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA
2002; 99: 16203–16208.
12 Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R
et al. Missing value estimation methods for DNA microarrays.
Bioinformatics 2001; 17: 520–525.
13 Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC.
ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate
with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Mol Cancer 2005; 4: 18–25.
14 Chiang YY, Chen SL, Hsiao YT, Huang CH, Lin TY, Chiang IP et al.
Nuclear expression of dynamin-related protein 1 in lung adenocarci-
nomas. Mod Pathol 2009; 22: 1139–1150.
15 Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG,
Joenje H et al. Disruption of the Fanconi anemia–BRCA pathway in
cisplatin-sensitive ovarian tumors. Nat Med 2003; 9: 568–574.
16 Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M et al. Identification
of c-myc responsive genes using rat cDNA microarray. Cancer Res 2000;
60: 5922–5928.
17 Balko JM, Black EP. A gene expression predictor of response to
EGFR-targeted therapy stratifies progression-free survival to cetuximab
in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009; 9:
145–154.
18 Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ et al. Phase II study of
docetaxel and irinotecan combination chemotherapy in metastatic
gastric carcinoma. Br J Cancer 2006; 94: 1402–1406.
19 Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ et al. Phase II study
of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric
carcinoma. Am J Clin Oncol 2005; 28: 433–438.
20 Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F et al.
Randomised multicentre phase III study comparing capecitabine with
fluorouracil and oxaliplatin with cisplatin in patients with advanced
oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol 2006; 24:
18s (abstr. 4017).
21 Pyrho ¨nen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison
of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus suppor-
tive care with supportive care alone in patients with non-resectable
gastric cancer. Br J Cancer 1995; 71: 587–591.
22 Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of
advanced gastric cancer. Expert Opin Emerg Drugs 2008; 13: 135–144.
23 Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S,
Cohen H et al. Thymidylate synthase mRNA level in adenocarcinoma of
the stomach: a predictor for primary tumor response and overall
survival. J Clin Oncol 1996; 14: 176–182.
24 Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ,
Hayashi K et al. ERCC1 mRNA levels complement thymidylate synthase
mRNA levels in predicting response and survival for gastric cancer
patients receiving combination cisplatin and fluorouracil chemother-
apy. J Clin Oncol 1998; 16: 309–316.
25 Dobbin KK, Simon RM. Optimally splitting cases for training and testing
high dimensional classifiers (submitted for publication) http://linus.
nci.nih.gov/Bbrb/reprints.htm.
26 Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I.
Amplification of c-myc, K-sam, and c-met in gastric cancers: detection
by fluorescence in situ hybridization. Lab Invest 1998; 78: 1143–1153.
27 Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G.
Epidermal growth factor receptor structural alterations in gastric cancer.
BMC Cancer 2008; 8: 10–15.
28 Yoshida T, Sakamoto H, Terada M. Amplified genes in cancer in upper
digestive tract. Semin Cancer Biol 1993; 4: 33–40.
2 9 L i e t oE ,F e r r a r a c c i oF ,O r d i t u r aM ,C a s t e l l a n oP ,M u r aA L ,P i n t oMet al.
Expression of vascular endothelial growth factor (VEGF) and epidermal
growth factor receptor (EGFR) is an independent prognostic indicator of
worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15: 69–79.
30 Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H.
Molecular–pathological prognostic factors of gastric cancer: a review.
Gastric Cancer 2005; 8: 86–94.
31 Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of
anti-epidermal growth factor receptor monoclonal antibodies plus
cis-diamminedichloroplatinum on well established A431 cell xenografts.
Cancer Res 1993; 53: 4637–4642.
32 Hiraishi Y, Wada T, Nakatani K, Uchida J, Iwasa T, Yoshida T et al.
Synergistic antitumor effect of S-1 and the epidermal growth factor
receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of
gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer
Ther 2008; 7: 599–606.
33 Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T
et al. Synergistic anti-tumor effects of FGFR2 inhibitor with
5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 2010; 126:
1004–1016.
34 Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M et al.
Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleo-
tides in a human metastatic melanoma inherently resistant to cisplatin.
Clin Cancer Res 1999; 5: 2588–2595.
35 Xie XK, Yang DS, Ye ZM, Tao HM. Recombinant antisense C-myc
adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to
cisplatin. Cancer Invest 2006; 24: 1–8.
36 Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to
chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung
carcinoma murine model. Anticancer Drugs 2003; 14: 39–47.
37 Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion
induced by c-Myc downregulation triggers apoptosis on treatment with
alkylating agents. Neoplasia 2004; 6: 195–206.
This work is licensed under the Creative
Commons Attribution-NonCommercial-No
DerivativeWorks3.0UnportedLicense.Toviewacopy
of this license, visit http://creativecommons.org/
licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (http://www.nature.
com/tpj)
Three-gene predictive signature for gastric cancer chemotherapy
HK Kim et al
127
The Pharmacogenomics Journal